WallStreetZenWallStreetZen

NYSEMKT: MTNB
Matinas Biopharma Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their MTNB stock forecasts and price targets.

Forecast return on equity

Is MTNB forecast to generate an efficient return?

Company
67.61%
Industry
118.65%
Market
267.67%
MTNB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MTNB forecast to generate an efficient return on assets?

Company
45.42%
Industry
34.65%
MTNB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MTNB earnings per share forecast

What is MTNB's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.53
Avg 2 year Forecast
-$5.10
Avg 3 year Forecast
$1.02

MTNB revenue forecast

What is MTNB's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$23.1M

MTNB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MTNB$1.38N/AN/A
VIVS$2.70N/AN/A
KPRX$2.31$10.00+332.90%Buy
QCLS$3.95N/AN/A
CDIO$4.04N/AN/A
View Top Biotech Stocks

Matinas Biopharma Holdings Stock Forecast FAQ

What is MTNB's earnings growth forecast for 2025-2027?

(NYSEMKT: MTNB) Matinas Biopharma Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.51%.

Matinas Biopharma Holdings's earnings in 2025 is -$19,609,000.On average, 3 Wall Street analysts forecast MTNB's earnings for 2025 to be -$7,783,087, with the lowest MTNB earnings forecast at -$7,477,868, and the highest MTNB earnings forecast at -$8,012,001. On average, 4 Wall Street analysts forecast MTNB's earnings for 2026 to be -$25,943,624, with the lowest MTNB earnings forecast at -$29,911,472, and the highest MTNB earnings forecast at -$21,365,337.

In 2027, MTNB is forecast to generate $5,188,725 in earnings, with the lowest earnings forecast at $4,985,245 and the highest earnings forecast at $5,341,334.

If you're new to stock investing, here's how to buy Matinas Biopharma Holdings stock.

What is MTNB's revenue growth forecast for 2025-2027?

(NYSEMKT: MTNB) Matinas Biopharma Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 283.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.18%.

Matinas Biopharma Holdings's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast MTNB's revenue for 2025 to be $0, with the lowest MTNB revenue forecast at $0, and the highest MTNB revenue forecast at $0. On average, 4 Wall Street analysts forecast MTNB's revenue for 2026 to be $0, with the lowest MTNB revenue forecast at $0, and the highest MTNB revenue forecast at $0.

In 2027, MTNB is forecast to generate $117,270,265 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $241,438,482.

What is MTNB's forecast return on assets (ROA) for 2025-2027?

(NYSEMKT: MTNB) forecast ROA is 45.42%, which is higher than the forecast US Biotechnology industry average of 34.65%.

What is MTNB's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSEMKT: MTNB) Matinas Biopharma Holdings's current Earnings Per Share (EPS) is -$3.89. On average, analysts forecast that MTNB's EPS will be -$1.53 for 2025, with the lowest EPS forecast at -$1.47, and the highest EPS forecast at -$1.58. On average, analysts forecast that MTNB's EPS will be -$5.10 for 2026, with the lowest EPS forecast at -$5.88, and the highest EPS forecast at -$4.20. In 2027, MTNB's EPS is forecast to hit $1.02 (min: $0.98, max: $1.05).

What is MTNB's forecast return on equity (ROE) for 2025-2027?

(NYSEMKT: MTNB) forecast ROE is 67.61%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.